Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Romain Corre

Showing results (11-20 of 54) with videos related to

Pageof 6
Sort By:
Bulletin Du Cancer|January 1, 2019
Alexandra Frelau, Marc Pracht, Samuel Le Sourd, et al.
Acta Oncologica (Stockholm, Sweden)|October 14, 2022
Immune checkpoint inhibitors in patients aged 80 or older with advanced non-small cell lung cancer or melanoma: a real-life multicentre studySoraya Benguerfi, Thierry Lesimple, Roch Houot, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 15, 2010
Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 studyAlain Vergnenegre, Romain Corre, Henri Berard, et al.
Clinical Lung Cancer|June 12, 2012
Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505)Christos Chouaid, Hervé Le Caer, Romain Corre, et al.
Lung Cancer (Amsterdam, Netherlands)|January 22, 2023
Reaching multidisciplinary consensus on the management of non-bulky/non-infiltrative stage IIIA N2 non-small cell lung cancerArnaud Scherpereel, Etienne Martin, Laurent Brouchet, et al.
Radiation Oncology (London, England)|August 15, 2018
Optimized radiotherapy to improve clinical outcomes for locally advanced lung cancerNicolas Jaksic, Enrique Chajon, Julien Bellec, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 22, 2009
A randomized phase II trial assessing in advanced non-small cell lung cancer patients with stable disease after two courses of cisplatin-gemcitabine an early modification of chemotherapy doublet with paclitaxel-gemcitabine versus continuation of cisplatin-gemcitabine chemotherapy (GFPC 03-01 Study)Alain Vergnenègre, Julie Tillon, Romain Corre, et al.
JTO Clinical and Research Reports|September 30, 2021
Brief Report on the Efficacy of Nivolumab in Patients With Previously Treated Advanced Large-Cell Neuroendocrine Cancer of the LungCamille Agar, Margaux Geier, Guillaume Léveiller, et al.
Therapeutic Advances in Medical Oncology|January 6, 2021
Nivolumab treatment in advanced non-small cell lung cancer: real-world long-term outcomes within overall and special populations (the UNIVOC study)Jean-Baptiste Assié, Romain Corre, Matteo Giaj Levra, et al.
JCO Clinical Cancer Informatics|February 3, 2022
Machine Learning-Based Analysis of Treatment Sequences Typology in Advanced Non-Small-Cell Lung Cancer Long-Term Survivors Treated With NivolumabChristos Chouaïd, Valentine Grumberg, Alexandre Batisse, et al.
Pageof 6

Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
Bulletin Du Cancer|January 1, 2019
Alexandra Frelau, Marc Pracht, Samuel Le Sourd, et al.
Acta Oncologica (Stockholm, Sweden)|October 14, 2022
Immune checkpoint inhibitors in patients aged 80 or older with advanced non-small cell lung cancer or melanoma: a real-life multicentre studySoraya Benguerfi, Thierry Lesimple, Roch Houot, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 15, 2010
Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 studyAlain Vergnenegre, Romain Corre, Henri Berard, et al.
Clinical Lung Cancer|June 12, 2012
Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505)Christos Chouaid, Hervé Le Caer, Romain Corre, et al.
Lung Cancer (Amsterdam, Netherlands)|January 22, 2023
Reaching multidisciplinary consensus on the management of non-bulky/non-infiltrative stage IIIA N2 non-small cell lung cancerArnaud Scherpereel, Etienne Martin, Laurent Brouchet, et al.
Radiation Oncology (London, England)|August 15, 2018
Optimized radiotherapy to improve clinical outcomes for locally advanced lung cancerNicolas Jaksic, Enrique Chajon, Julien Bellec, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 22, 2009
A randomized phase II trial assessing in advanced non-small cell lung cancer patients with stable disease after two courses of cisplatin-gemcitabine an early modification of chemotherapy doublet with paclitaxel-gemcitabine versus continuation of cisplatin-gemcitabine chemotherapy (GFPC 03-01 Study)Alain Vergnenègre, Julie Tillon, Romain Corre, et al.
JTO Clinical and Research Reports|September 30, 2021
Brief Report on the Efficacy of Nivolumab in Patients With Previously Treated Advanced Large-Cell Neuroendocrine Cancer of the LungCamille Agar, Margaux Geier, Guillaume Léveiller, et al.
Therapeutic Advances in Medical Oncology|January 6, 2021
Nivolumab treatment in advanced non-small cell lung cancer: real-world long-term outcomes within overall and special populations (the UNIVOC study)Jean-Baptiste Assié, Romain Corre, Matteo Giaj Levra, et al.
JCO Clinical Cancer Informatics|February 3, 2022
Machine Learning-Based Analysis of Treatment Sequences Typology in Advanced Non-Small-Cell Lung Cancer Long-Term Survivors Treated With NivolumabChristos Chouaïd, Valentine Grumberg, Alexandre Batisse, et al.
Pageof 6